Editor's Note: This article was originally published on Real Money at 12:52 p.m. EDT on May 10. To see Jim Cramer's latest commentary as it's published, sign up for a free trial of Real Money.NEW YORK ( Real Money) -- So, Celgene (CELG - Get Report), Regeneron (REGN - Get Report), Biogen Idec (BIIB - Get Report) and Alexion (ALXN - Get Report) rested, recharged and now are returning to their winning ways. Only Gilead (GILD - Get Report) has yet to turn to the black, which means it's probably time to buy that one, too. These stocks had the classic kind of recharge that you want to see if you are a bull. They must be as annoying as all get out if you are a bear because all that seems to happen with them is that people pay more for the same news over and over in classic multiple-expansion theory. That's always regarded as a total red flag by the purists, but has worked just fine for ages now, so it has made all of these a tough short. Take Regeneron, one of my absolute favorites with the best macular degeneration drug. The company reported spectacular results and then rallied, although the results were spectacular if you actually just came to believe that Regeneron isn't that good. It sure is. Then it got added to the S&P, which caused a short spike. The usual arbitrageurs then shorted the stock, betting post admission it would give up the ghost. But virtually at the same moment that it was added, Allergan announced, in a true shocker, that its competitive drug to Regeneron wasn't up to snuff -- yet --and that caused the next spike up. Then the market rotated to the materials stocks, which are giving up the ghost today, and the move is now back in full swing based on, well, a rotation back into these stocks as the market takes note of the pipelines and the scrips that remain strong. That means you can go back to Biogen, which people are doing right now as the MS scrips are real good. And I suspect they will go back to Gilead, too, as there's tons of drugs in the pipeline there, too. Just a natural change in leadership from specs and materials back to what brought us up here in the first place. Action Alerts PLUS, which Cramer co-manages as a charitable trust, has no positions in the stocks mentioned.
Cramer: Biotech Makes a Comeback
May 10, 2013 | 04:39 PM EDT
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.